Posted by Michael Wonder on 14 Feb 2020
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
13 February 2020 - Potential risk of cancer outweighs the benefits.
The U.S. FDA has requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer.
The drug manufacturer, Eisai, has submitted a request to voluntarily withdraw the drug.
